Home
World Journal of Biology Pharmacy and Health Sciences
ISSN Approved | International, Peer reviewed, Referred, Open access Journal

Main navigation

  • Home
    • Journal Information
    • Abstracting and Indexing
    • Editorial Board Members
    • Reviewer Panel
    • Journal Policies
    • WJBPHS CrossMark Policy
    • Publication Ethics
    • Current Issue
    • Issue in Progress
    • Past Issues
    • Instructions for Authors
    • Article processing fee
    • Track Manuscript Status
    • Get Publication Certificate
    • Become a Reviewer panel member
    • Join as Editorial Board Member
  • Contact us
  • Downloads

ISSN Approved Journal | | IMPACT FACTOR 8.16 | | eISSN: 2582-5542 | |  Free Crossref DOI 

Fast Publication within 2 days | | Low Article Processing Charges | | Peer Reviewed and Referred Journal

Research and review articles are invited for publication in September 2026 (Volume 27, Issue 3) Submit Paper

Monoclonal antibodies: Pioneering the future of medicine

Breadcrumb

  • Home
  • Monoclonal antibodies: Pioneering the future of medicine

Deepika Rajput, Mohammad Khalid *, Shubham Pratap Singh, Megha Gupta and Ankit Kumar

Krishna Pharmacy College, Bijnor, Uttar Pradesh, India – 246701.

Review Article

World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 083-087

Article DOI: 10.30574/wjbphs.2025.21.1.1074

DOI url: https://doi.org/10.30574/wjbphs.2025.21.1.1074

Received on 15 November 2024; revised on 29 December 2024; accepted on 31 December 2024

Large-scale manufacturing procedures have been developed in response to the growing demand for monoclonal antibodies (mAbs) utilized in therapeutic and diagnostic applications. Continuous optimization of the underlying systems has improved product. Numerous enhancements and changes to monoclonal antibodies have been devion. In response to mAb limitations and side effects, the number of monoclonal antibodies (mAbs) that have previously been approved for use in clinical trials and therapeutic applications has expanded dramatically in recent years. These changes have made it easier to employ mAbs in a variety of therapeutic applications, including the management of infectious disorders brought on by parasitic, bacterial, viral, and fungal organisms. Additionally Monoclonal antibodies have been utilized to treat Non-infectious diseases such as cancer, immunological problems, and arthritis, , and problems caused by organ donation. This review looks at cutting-edge technology related to the potential application of mAbs in biomedicine.

Monoclonal antibodies (mAbs); Antibody engineering; Humanized MAbs (HMAs); Target antigen; Radiolabeled antibodies

https://wjbphs.com/sites/default/files/fulltext_pdf/WJBPHS-2024-1074.pdf

Preview Article PDF

Deepika Rajput, Mohammad Khalid, Shubham Pratap Singh, Megha Gupta and Ankit Kumar. Monoclonal antibodies: Pioneering the future of medicine. World Journal of Biology Pharmacy and Health Sciences, 2025, 21(01), 083-087. Article DOI: https://doi.org/10.30574/wjbphs.2025.21.1.1074.

Get Certificates

Get Publication Certificate

Download LoA

Check Corssref DOI details

Issue details

Issue Cover Page

Editorial Board

Table of content


Copyright © Author(s). All rights reserved. This article is published under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as appropriate credit is given to the original author(s) and source, a link to the license is provided, and any changes made are indicated.


Copyright © 2026 World Journal of Biology Pharmacy and Health Sciences (WJBPHS) - All rights reserved

Developed & Designed by VS Infosolution